<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03412383</url>
  </required_header>
  <id_info>
    <org_study_id>NCC201711008</org_study_id>
    <nct_id>NCT03412383</nct_id>
  </id_info>
  <brief_title>Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer</brief_title>
  <official_title>A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 20, 2018</start_date>
  <completion_date type="Anticipated">June 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>From date of first use Pyrotinib until the date of first documented progression or date of death from any cause, whichever came first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Adverse events (AEs) and laboratory tests graded according to the NCI CTCAE (version 4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response rates (ORR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Defined as complete response (CR) + partial response (PR), assessed based on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit rate (CBR)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Defined as CR+PR+stable disease (SD), assessed based on on Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Time from first use Pyrotinib to disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life(QoL)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Using the EORTC quality of life questionnaire QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 52 months</time_frame>
    <description>Time from first use Pyrotinib to death</description>
  </secondary_outcome>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Breast Cancer</condition>
  <condition>HER2 Gene Mutation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>Pyrotinib 400mg/day</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Able to understand and willing to sign an Institutional Review Board（IRB） approved written
        informed consent document.

        At least 18 years of age. Histologically or cytologically confirmed HER2-negative (0 or 1+
        by immuno-histochemical (IHC) or non-amplified by FISH) breast cancer that is stage IV.

        There is no standard therapy. At least one measurable disease by RECIST 1.1 is required.
        Karnofsky performance status (KPS)&gt;70, life expectancy &gt; 12 weeks

        Exclusion Criteria:

        Lack of adequate organ function as defined below within 2 weeks of registration:

        Absolute neutrophil count (ANC)&lt;1.5×109/L，platelet counts (PLT)&lt;75×109/L or hemoglobin
        (Hb)&lt;100g/L Total bilirubin (TBiL)&gt;2×upper limit of normal (ULN); Aspartate
        aminotransferase (AST) or alanine aminotransferase (ALT)&gt;2.5×ULN（or&gt;5 x ULN for patients
        with liver metastases）; Alkaline phosphatase (ALP)&gt;2.5×ULN; serum creatinine concentration
        (Scr)&gt;140umol/L Pregnant and/or breastfeeding. History of significant cardiac disease,
        cardiac risk factors, or uncontrolled arrhythmias.

        Having a history of uncontrolled paroxysmal diseases, including central nervous system
        diseases or mental disorders which may have an impact on the understanding and signature of
        informed consent Uncontrolled acute infection Currently receiving any other investigational
        agents or systemic cancer therapy.

        Allergy to any investigational drug ; Any other condition that investigator considers
        inappropriate to participate in this trail
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Ma</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fei Ma, MD</last_name>
    <phone>+86-10-87787652</phone>
    <email>mafei@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fei Ma</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Ma, MD</last_name>
      <phone>+86-10-87787652</phone>
      <email>mafei@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2018</study_first_submitted>
  <study_first_submitted_qc>January 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2018</study_first_posted>
  <last_update_submitted>January 28, 2018</last_update_submitted>
  <last_update_submitted_qc>January 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College</investigator_affiliation>
    <investigator_full_name>Fei Ma</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

